231 related articles for article (PubMed ID: 11304766)
1. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of nelarabine in indolent leukemias.
Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
[TBL] [Abstract][Full Text] [Related]
3. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
Gandhi V; Plunkett W; Rodriguez CO; Nowak BJ; Du M; Ayres M; Kisor DF; Mitchell BS; Kurtzberg J; Keating MJ
J Clin Oncol; 1998 Nov; 16(11):3607-15. PubMed ID: 9817282
[TBL] [Abstract][Full Text] [Related]
4. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
[TBL] [Abstract][Full Text] [Related]
5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
6. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
Kisor DF
Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Gandhi V; Estey E; Keating MJ; Plunkett W
J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
[TBL] [Abstract][Full Text] [Related]
11. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.
Rodriguez CO; Plunkett W; Paff MT; Du M; Nowak B; Ramakrishna P; Keating MJ; Gandhi V
J Chromatogr B Biomed Sci Appl; 2000 Aug; 745(2):421-30. PubMed ID: 11043760
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
13. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Gandhi V; Robertson LE; Keating MJ; Plunkett W
Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
[TBL] [Abstract][Full Text] [Related]
14. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.
Kisor DF; Plunkett W; Kurtzberg J; Mitchell B; Hodge JP; Ernst T; Keating MJ; Gandhi V
J Clin Oncol; 2000 Mar; 18(5):995-1003. PubMed ID: 10694549
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
[TBL] [Abstract][Full Text] [Related]
17. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Aguayo A; Cortes JE; Kantarjian HM; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating MJ
Cancer; 1999 Jan; 85(1):58-64. PubMed ID: 9921974
[TBL] [Abstract][Full Text] [Related]
18. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]